Coats on for Starpharma
Tuesday, 09 September, 2008
Starpharma [ASX: SPL] has licensed the marketing rights to its VivaGel coated condom to SSL International, owners of the market-leading Durex condom brand.
Under the agreement, SSL has been granted the right to marketing the VivaGel condom in most of the world, including Europe and the US.
The agreement could be worth at least $100 million in royalties, milestone payments and development support to Starpharma.
Starpharma is continuing to develop VivaGel as an applicator-delivered vaginal product designed to help women protect themselves from HIV and genital herpes.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
